ReviewPaediatric drugs2012
Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Review in Paediatric drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Tuberous sclerosis complex with multisystem involvement: A case report.The Journal of international medical research · 2026Article
- The transcriptomic signature of DEPDC5 KO induced mTOR hyperactivation in human neurons and its response to rapamycin treatment.Epilepsia · 2025Article
- Review
- Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.International journal of medical sciences · 2023Article
- Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.CNS drugs · 2021Article
- Metabolomic studies identify changes in transmethylation and polyamine metabolism in a brain-specific mouse model of tuberous sclerosis complex.Human molecular genetics · 2018Article
- Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays.Oncotarget · 2017Review
- New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).F1000Research · 2017Review
- Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.British journal of clinical pharmacology · 2016Review
- Review
- Personalized medicine in neuro-oncology.CNS oncology · 2016Article
- Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment.International journal of molecular sciences · 2015Review
- Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.Biochemical and biophysical research communications · 2015Article
- The mTOR signaling pathway as a treatment target for intracranial neoplasms.Neuro-oncology · 2015Review
- Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells.Cancer biology & therapy · 2015Article
- mTOR kinase: a possible pharmacological target in the management of chronic pain.BioMed research international · 2015Review
- t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.The American journal of surgical pathology · 2014Article
- Current approaches to the treatment of metastatic brain tumours.Nature reviews. Clinical oncology · 2014Review
- Review
- Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR.The Indian journal of medical research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0 mg/m(2)) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patients aged ≥3 years with tuberous sclerosis complex (TSC) in a phase II trial (C2485). At 6 months, 32% of patients treated with everolimus had a ≥50% reduction in the volume of their largest SEGA lesion (assessed via an independent central radiology review); 75% had a ≥30% reduction. No patients developed new lesions. During the extension phase of this trial (median duration 34 months), the reduction in SEGA volume was maintained, with no everolimus recipient requiring surgery or other therapy for SEGA or hydrocephalus. In a phase III trial (EXIST-1) in 117 patients with SEGA associated with TSC, 35% of everolimus recipients (starting dosage 4.5 mg/m(2)) versus none of the placebo recipients (p < 0.0001) had an overall response (a reduction in the sum of all target SEGA volumes of ≥50% relative to baseline, nonworsening of non-target SEGA lesions, no new SEGA lesions, and no new/worsening hydrocephalus). Everolimus was generally well tolerated in patients with SEGA associated with TSC; most drug-related adverse reactions were mild to moderate in severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.